TSHA
Taysha Gene Therapies, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
6.02
P/S
119.03
EV/EBITDA
-7.96
DCF Value
$0.59
FCF Yield
-8.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.0%
Operating Margin
-1130.6%
Net Margin
-1115.3%
ROE
-56.6%
ROA
-31.7%
ROIC
-34.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $5.5M | $-27.9M | $-0.08 |
| FY 2025 | $9.8M | $-109.0M | $-0.34 |
| Q3 2025 | $0.00 | $-32.7M | $-0.09 |
| Q2 2025 | $2.0M | $-26.9M | $-0.09 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.08
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.